RT期刊文章SR电子T1保护抗乙酰氨酸诱导的支气管痉挛：Salbutamol PMDI相对Clickhaler®DPIJF欧洲呼吸杂志JO EUR呼吸J FD欧洲呼吸协会SP 816 OP 820 DO 10.1183/09188bet官网地址031936.03.00045902 VO 21 IS 5 A1 NEWHOUSE，M.T。A1 Patel，P。A1 Parry-billings，M。YR 2003 UL //www.qdcxjkg.com/content/21/5/816.abstract Abs Track ab sashive Dry-Powder吸入器（DPIS）是作为替代品的替代方法加压计量剂量吸入器（PMDIS）以改善吸入时的气溶胶输送并消除了推进剂的需求。但是，与常规PMDI疗法相比，必须严格地将仿制药的新DPI配方进行。这项随机，双盲，双重，安慰剂对照，七向跨界研究评估了甲杆菌挑战的支气管保护措施，以便将新颖的Salbutamol DPI（Clickhaler®）与参考Salbutamolpmdi（ventolin®）进行比较。成年气道哮喘患者对甲基胆碱的高反应性（挑衅性浓度浓度，导致20％的乙醇浓度在一秒钟（PC20）<4 mg·ml -1中下降了20％ µg of salbutamol via the DPI or pMDI. Methacholine challenge was performed before and after salbutamol treatment and the PC20 ratios analysed by Finney's bioassay to test for therapeutic equivalence of the inhalers. Eighteen patients completed the study and showed significant dose-related responses to salbutamol. The relative potency of DPI:pMDI was 1.29 (90% confidence interval 1.04–1.63). There were no treatment differences in safety (cardiac frequency, blood pressure, adverse events). Methacholine-challenge methodology provides a sensitive bioassay and has demonstrated therapeutic equivalence of the salbutamol Clickhaler® dry-powder inhaler with the conventional salbutamol pressurised metered-dose inhaler. This study was supported by Innovata Biomed Ltd.